Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
APLM | US
0.01
6.79%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.14
0.13
0.14
0.13
Apollomics Inc. a biotechnology company engages in the discovery and development of oncology therapies to address unmet medical needs in California Hangzhou Shanghai China and Australia. It develops APL-101 (Vebreltinib) a potent selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active small molecule multiple tyrosine kinase inhibitor for liver cancer breast cancer and esophageal cancer; and APL-122 a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals Inc. and changed its name to Apollomics Inc. in January 2019. Apollomics Inc. was incorporated in 2015 and is based in Foster City California.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
76.7%1 month
84.4%3 months
85.1%6 months
82.4%-
-
0.68
0.21
0.13
-0.10
-
-
-53.10M
15.04M
15.04M
-
-1.43K
-
262.30
-149.31
0.27
0.26
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.04
Range1M
0.06
Range3M
0.18
Rel. volume
1.09
Price X volume
127.10K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.244 | 15.97M | 0.16% | n/a | 118.63% |
Indaptus Therapeutics Inc. Common Stock | INDP | Biotechnology | 1.47 | 14.99M | -2.63% | n/a | 2.12% |
Cingulate Inc. Common Stock | CING | Biotechnology | 4.92 | 14.98M | 7.19% | n/a | 10.72% |
ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.5352 | 14.94M | -0.89% | n/a | 49.00% |
Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
Evogene Ltd | EVGN | Biotechnology | 2.58 | 14.44M | 7.50% | n/a | 26.41% |
IMNN | IMNN | Biotechnology | 0.9925 | 14.29M | 0.71% | n/a | 37.13% |
Evaxion Biotech A/S | EVAX | Biotechnology | 2.54 | 14.17M | -3.79% | n/a | 837.11% |
Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.10 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 0.68 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 85.08 | 72.80 | Par |
Debt to Equity | 0.21 | -1.23 | Expensive |
Debt to Assets | 0.13 | 0.25 | Cheaper |
Market Cap | 15.04M | 3.66B | Emerging |